Literature DB >> 20508618

Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines.

S K Rathe, D A Largaespada.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20508618     DOI： 10.1038/leu.2010.88

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia.

Authors:  Susan K Rathe; Branden S Moriarity; Christopher B Stoltenberg; Morito Kurata; Natalie K Aumann; Eric P Rahrmann; Natashay J Bailey; Ellen G Melrose; Dominic A Beckmann; Chase R Liska; David A Largaespada
Journal:  Sci Rep       Date:  2014-08-13       Impact factor: 4.379

2.  Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.

Authors:  Morito Kurata; Susan K Rathe; Natashay J Bailey; Natalie K Aumann; Justine M Jones; G Willemijn Veldhuijzen; Branden S Moriarity; David A Largaespada
Journal:  Sci Rep       Date:  2016-11-03       Impact factor: 4.379

Review 3.  Digging deep into "dirty" drugs - modulation of the methylation machinery.

Authors:  Lisa Pleyer; Richard Greil
Journal:  Drug Metab Rev       Date:  2015-01-08       Impact factor: 4.518

4.  Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.

Authors:  D Malani; A Murumägi; B Yadav; M Kontro; S Eldfors; A Kumar; R Karjalainen; M M Majumder; P Ojamies; T Pemovska; K Wennerberg; C Heckman; K Porkka; M Wolf; T Aittokallio; O Kallioniemi
Journal:  Leukemia       Date:  2016-11-11       Impact factor: 11.528

5.  Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia.

Authors:  Han Yan; Lu Wen; Dan Tan; Pan Xie; Feng-Mei Pang; Hong-Hao Zhou; Wei Zhang; Zhao-Qian Liu; Jie Tang; Xi Li; Xiao-Ping Chen
Journal:  Oncotarget       Date:  2017-01-03

6.  Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase IIα as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin.

Authors:  Bibi Kulsoom; Tahir Sultan Shamsi; Nasir Ali Afsar
Journal:  Cancer Manag Res       Date:  2018-11-09       Impact factor: 3.989

7.  Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.

Authors:  May Levin; Michal Stark; Bluma Berman; Yehuda G Assaraf
Journal:  Cell Death Dis       Date:  2019-05-17       Impact factor: 8.469

8.  Cytarabine-Resistant FLT3-ITD Leukemia Cells are Associated with TP53 Mutation and Multiple Pathway Alterations-Possible Therapeutic Efficacy of Cabozantinib.

Authors:  Ya-Chen Ko; Chung-Yi Hu; Zheng-Hau Liu; Hwei-Fang Tien; Da-Liang Ou; Hsiung-Fei Chien; Liang-In Lin
Journal:  Int J Mol Sci       Date:  2019-03-11       Impact factor: 5.923

9.  Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.

Authors:  May Levin; Michal Stark; Yishai Ofran; Yehuda G Assaraf
Journal:  Cancer Cell Int       Date:  2021-01-14       Impact factor: 5.722

10.  Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Authors:  A Valencia; E Masala; A Rossi; A Martino; A Sanna; F Buchi; F Canzian; D Cilloni; V Gaidano; M T Voso; O Kosmider; M Fontenay; A Gozzini; A Bosi; V Santini
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.